Clinical trials: Soft Tissue and Bone Tumor
Breast Cancer, Gynecologic Cancer
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
The Stanford Cancer Center is undertaking a Transformation Initiative in order to improve the quality of care and care coordination across the continuum of care.
- Conditions
- Breast Cancer, Gynecologic Cancer, Neck Cancer, Head and Neck Cancer
- Trial name
- NCT03245788
- Testing
- Lay Navigation
- Where
- United States
- Volunteers
- 1,053 people
- Sponsor
- Stanford University
Neuroblastoma, Relapsed Neuroblastoma
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
Subjects with relapsed or refractory neuroblastoma and osteosarcoma will receive ex-vivo expanded and activated natural killer (NK) cells from a haploidentical donor in conjunction with the immunocytokine, hu14.18-IL2.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma, Osteosarcoma
- Trial name
- NCT03209869
- Testing
- Ex vivo Expanded and Activated Haploidentical Donor NK Cells, Hu14.18-IL2
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Osteosarcoma, Bone Cancer
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma.
- Trial name
- IACE-OS (NCT06562673)
- Testing
- intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai 6th People's Hospital
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb